New codes for two health apps introduced in the German Uniform Evaluation Standard (EBM) catalog

The updated German Uniform Evaluation Standard (EBM) catalog came into force on October 1, 2023. The EBM catalog (Einheitlicher Bewertungsmaßstab) regulates the reimbursement of services in the public outpatient sector in Germany and is updated once a quarter (four times a year). Among other changes, a new code for “Mawendo” and “Oviva Direkt für Adipositas” health apps were introduced in the catalog. 

The newly introduced codes with tariffs are provided below:

• 01475 “Additional flat rate for the follow-up and evaluation of the digital health application (DiGA) Oviva Direkt for obesity in line with the Directory for digital health applications according to §139e SGB V” with a tariff of €7.35;
• 01476 “Additional flat rate for the selection and/or individualization of the content of the digital health application (DiGA) Mawendo in line with the Directory for digital health applications according to §139e SGB V” with a tariff of €7.35.

“Oviva Direkt für Adipositas” is a health app developed for the treatment (multimodal obesity therapy) of severe obesity and support of patients in changing their habits and reducing their weight.

“Mawendo” health app provides training programs with exercise videos, health information, and documentation options. The training program is initially selected by physicians and individualized for the patient in terms of the clinical picture, the specific exercises, and the training phases. With the help of this app, the patients can then independently support the treatment of diseases of the kneecap (patella) through their own training.

The full details in German can be found here, here (Oviva Direkt für Adipositas), and here (Mawendo).

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.